Back

Transient JAK/STAT inhibition by ruxolitinib modulates malaria-specific CD4+ T cell responses and enhances recall immunity in volunteers experimentally infected with Plasmodium falciparum.

2025-04-11 allergy and immunology Title + abstract only
View on medRxiv
Show abstract

Type I interferon (IFN) signalling promotes development of type 1 regulatory (Tr1) CD4+ T cells, which suppress inflammation but may limit protective immunity in malaria by constraining effector Th1 cells and antibody-promoting T follicular helper (Tfh) cells. We tested whether transiently blocking IFN-driven JAK/STAT signalling with ruxolitinib would reduce Tr1 cell development and enhance protective Th1 and Tfh cell responses. Using controlled human malaria infection, we investigated the impac...

Predicted journal destinations